Add BrightSurf on Google Email

The Lancet


Alcohol: The forgotten drug in HIV/AIDS

A new study finds that hazardous alcohol consumption is linked to increased HIV infection rates in Southern and Eastern Africa. Venue-based interventions have been shown to be effective in changing individual behavior and social norms, but more research is needed to address the gender gap in these programs.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 20, 2010

Vitamin A deficiency in New York City

A 24-year-old pregnant woman was diagnosed with vitamin A deficiency due to poor diet and intestinal absorption issues. Following vitamin A supplementation, her vision returned to normal, highlighting the importance of proper nutrition and diagnosis for potentially curable forms of blindness.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 18, 2010

The battle to be researchers in the oPt

Despite these challenges, Palestinian researchers were able to attend a conference on global health issues, showcasing their resilience and determination. The conference, hosted by the Lancet-Palestinian Health Alliance, brought together international and local experts to discuss population health in the context of occupation.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 1, 2010

A Palestinian perspective on aid

A Palestinian perspective on aid critiques the politics behind aid provided to the occupied territory, highlighting how it maintains an unacceptable situation. The authors argue that generous aid subsidizes Israel's expansion and perpetuates donor dependency, with 42% of health expenditure financed by donors.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 1, 2010

1 in 4 Palestinian children goes without breakfast

A recent study published in The Lancet finds that 26% of Palestinian children skip breakfast, leading to concerns over anaemia, stunting, and poor eating habits. The study suggests that comprehensive school nutrition programs are needed to address these issues and promote healthy eating habits among all age groups.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 1, 2010

The terror of childbirth under siege

The article shares harrowing accounts of women who gave birth during the Israeli assault on Gaza strip in December 2008 and January 2009. The women described severe trauma, complications such as sepsis and hypothermia, and their heroic struggles to survive with their families amidst destruction.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 1, 2010

Intensive therapy improves some outcomes for patients with established type 2 diabetes but also increases risk of death, weight gain, and hypoglycemia (from ACCORD study)

The ACCORD study found that intensive glucose treatment delayed albuminuria onset but didn't reduce microvascular complications like eye disease or kidney failure. However, it increased mortality, weight gain, and severe hypoglycemia risk, prompting a shift to standard therapy.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 29, 2010

Unexpected findings in patients with limbic encephalitis will change disease diagnosis and classification and aid understanding of other neurological diseases

Researchers identify LGI1 as the main target of autoantibodies in patients with limbic encephalitis, leading to a new diagnostic test and potential therapeutic strategies for other neurological disorders. The findings also suggest that limbic encephalitis should be classified as an autoimmune synaptic encephalopathy.

SourceThe Lancet_DELETED·JournalThe Lancet Neurology·DateJun 27, 2010

Once-weekly exenatide injection improves blood sugar control more than daily oral sitagliptin or pioglitazone and induces more weight loss (DURATION-2 study)

The DURATION-2 study found that once-weekly exenatide improved HbA1c levels by 1.5% compared to 0.9% for sitagliptin and 1.2% for pioglitazone, with significant weight loss in the exenatide group. The findings suggest that exenatide should be considered as an adjunct to metformin for improving glucose control and weight loss.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 26, 2010

Once weekly exenatide for type 2 diabetes is more convenient and induces better blood sugar control and more weight loss, than standard second-line treatment of daily insulin glargine

A 26-week randomized study found that once-weekly exenatide significantly improved blood sugar control, inducing a mean weight loss of 2.6kg per patient, compared to insulin glargine's lesser effect and mean weight gain of 1.4kg. The treatment also had lower rates of hypoglycemia and a progressive decrease in bodyweight.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 24, 2010

Pre-meal technosphere inhaled insulin plus once daily insulin glargine leads to similar blood sugar control and less weight gain than twice daily premixed biaspart insulin

A randomized study found that inhaled insulin plus insulin glargine achieved similar blood sugar control as twice-daily premixed biaspart insulin, with less weight gain and hypoglycemia. The treatment also showed a better safety profile, with fewer cough and lung function issues.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 24, 2010

Genetic factors affect risk of vitamin D insufficiency

A genome-wide association study found three genetic variants significantly associated with vitamin D concentrations and risk of insufficiency. Participants with certain genotypes were at two-and-a-half times increased risk of having low vitamin D levels, highlighting the importance of genetic factors in regulating vitamin D status.

SourceThe Lancet_DELETED·JournalThe Lancet·DateJun 9, 2010